Toggle Nav
My Cart
English
Español
Menu
Account
  • Log in / Register
    • Language
    English
    Español

    The Flaxil Label (A)

    Barron, Gregory

    • Reference: HBS-909001-E

    • Year: 2001

    • Number of pages: 10

    • Publication Date: Aug 24, 2008

    • Fecha de edición: Sep 2, 2008

    • Source: HBSP (USA)

    • Type of Document: Case

    • Industry Setting: Pharmaceuticals

    Grouped product items
    Format Language Reference Use Qty Price
    pdf English HBS-909001-E
    As low as €8.20

    You already have a subscription
    To order please contact the person in charge of academic purchases in your university.
    You'll be able to order once your profile has been validated.

    Description

    This case focuses on the 2001 negotiation between Mytex Pharmaceuticals and the U.S. Food and Drug Administration (FDA). The outcome of the negotiation would determine the new label for Mytex's blockbuster drug for arthritis, Flaxil. The negotiation is quite qualitative and differs from the typical price negotiation with which students are familiar. However, at stake was $500 million in Flaxil sales and the safety of millions of patients. The (A) case presents the perspective of Mytex and the FDA on new data suggesting the Flaxil may have a side effect.

    Related Documents

    Keywords

    Cognitive psychology Consumer behavior International business Negotiation Risk management